alergia - Spray de acetonido de triamcinolona pode ser melhor escolha na rinite alérgica
Esta página já teve 113.929.107 acessos - desde 16 maio de 2003. Média de 27.869 acessos diários
home | entre em contato
 

alergia

Spray de acetonido de triamcinolona pode ser melhor escolha na rinite alérgica

31/03/2006

 

Vários dos atributos sensoriais do extrato aquoso de triamcinolona (TAA) foram preferidos aos do furoato de mometasona (MF) e do propionato de fluticasona (FP). A preferência do paciente pode desempenhar um papel-chave na melhora da adesão ao tratamento. Estes achados indicam que o spray nasal de acetonido de triamcinolona (TAA) pode ser uma melhor escolha do que o furoato de mometasona (MF) e o propionato de fluticasona (FP) no tratamento das rinites alérgicas intermitentes e perene.

 

Annals of Allergy, Asthma and Immunology

2002, vol. 89, no. 3, pp. 292 - 297

 

Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis

Claus Bachert MD,PhD; Tarek El-Akkad MD

 

Abstract

Background: Although they have comparable safety and efficacy profiles, different intranasal corticosteroids possess different sensory/chemical properties that can be easily differentiated by patients, and which may influence their preference and compliance.

Objective: We sought to compare patient assessments of sensory attributes of three intranasal corticosteroid sprays: triamcinolone acetonide aqueous (TAA), fluticasone propionate (FP), and mometasone furoate (MF).

Methods: In a multicenter, randomized, double-blind, crossover study, 95 patients with allergic rhinitis rated 14 sensory items (100-point scales), product preference, and likelihood of compliance with treatment.

Results: Immediately after administration, compared with MF, TAA was rated as having significantly better comfort during administration, less irritation, less odor strength, preferred odor, more moistness of nose/throat, milder taste (allP ≤ 0.001), and preferred taste (P ≤ 0.01). Compared with FP, TAA was rated as having significantly less odor strength, preferred odor (both P ≤ 0.001), more moistness of nose/throat (P ≤ 0.01), and milder taste (P ≤ 0.05). Two minutes after application, TAA was rated as having less aftertaste than FP (P ≤ 0.01) or MF (P ≤ 0.001), and produced significantly less irritation (FP P ≤ 0.05; MF P ≤ 0.01). Of patients, 54.7% said they would prefer a prescription of TAA over one for MF (24.2%; P = 0.001) or FP (21.1%;P = 0.001). More patients indicated that they would be more compliant with treatment if given the TAA prescription (67.4%) than if given a prescription with FP (54.7%) or MF (49.5%).

Conclusion: Several of the TAA sensory attributes were preferred over those of MF and FP. Patient preference may play a role in enhancing treatment compliance. Such findings indicate that TAA nasal spray may be a better choice than MF or FP in the treatment of seasonal and perennial allergic rhinitis.

 

Annals of Allergy, Asthma and Immunology

2002, vol. 89, no. 3, pp. 292 - 297

 


IMPORTANTE

  •  Procure o seu médico para diagnosticar doenças, indicar tratamentos e receitar remédios. 
  • As informações disponíveis no site da Dra. Shirley de Campos possuem apenas caráter educativo.
Publicado por: Dra. Shirley de Campos
versão para impressão

Desenvolvido por: Idelco Ltda.
© Copyright 2003 Dra. Shirley de Campos